TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of “Moderate Buy” from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $40.67.

Several research firms have recently weighed in on TGTX. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. The Goldman Sachs Group boosted their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright increased their price target on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock. Finally, StockNews.com cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $32.16 on Friday. The stock’s 50 day moving average is $29.96 and its 200 day moving average is $24.24. TG Therapeutics has a one year low of $12.84 and a one year high of $36.84. The firm has a market cap of $5.01 billion, a P/E ratio of -321.57 and a beta of 2.25. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same quarter last year, the firm posted $0.73 EPS. The firm’s revenue for the quarter was down 49.4% on a year-over-year basis. As a group, research analysts expect that TG Therapeutics will post 0.17 EPS for the current year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. State Street Corp increased its stake in TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after buying an additional 2,398,015 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of TG Therapeutics during the second quarter valued at approximately $36,501,000. Hood River Capital Management LLC lifted its holdings in TG Therapeutics by 6.7% during the second quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock worth $27,982,000 after acquiring an additional 98,892 shares during the period. Charles Schwab Investment Management Inc. boosted its position in TG Therapeutics by 0.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company’s stock worth $27,708,000 after purchasing an additional 7,939 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.